|File:(±)-Doxazosin Structural Formulae.png|
|Systematic (IUPAC) name|
|Biological half-life||22 hours|
|ATC code||C02CA04 (WHO)|
|Molar mass||451.475 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
It is an alpha-1 adrenergic receptor blocker that inhibits the binding of norepinephrine (released from sympathetic nerve terminals) to the alpha-1 receptors on the membrane of vascular smooth muscle cells. The primary effect of this inhibition is relaxed vascular smooth muscle tone (vasodilation), which decreases peripheral vascular resistance, leading to decreased blood pressure.
In Egypt, tablet formulation sold as Duracin produced by Biopharm group for research and the drug industry, Dosin by Eipico and Doxazocine by Multi-Apex.
In March 2000, the ALLHAT study stopped its arm of the trial looking at alpha blockers, because doxazosin (Cardura) was less effective than a simple diuretic, and because patients on Cardura had a 25% higher rate of cardiovascular disease and twice the rate of congestive heart failure as patients on diuretics. Pfizer, aware of the results before publication, launched a sophisticated damage-control campaign in early 2000, and sales were largely unaffected, despite the dangers highlighted by the study.
Recent Studies have given new rise to a preference for Doxazosin as a BPH Drug, as it was found to increase erectile function. The company’s own study did not yield as statistically significant results; however, Doxazosin does show promise for men with BPH and ED.
- Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- "Marketing: Spin doctors soft pedal data on antihypertensives". BMJ. 2003-01-18. Retrieved 2008-05-26.
- "Antihypertensive Drugs and Patients With Erectile Dysfunction".
|40px||This antihypertensive-related article is a stub. You can help ssf by expanding it.|
|40px||This drug article relating to the genito-urinary system is a stub. You can help ssf by expanding it.|